Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...
News-Medical.Net on MSN
Recent advances in CAR-NK cell therapy could revolutionze cancer treatment
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...
CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...
COEPTIS, Inc. has established GEAR Therapeutics as a majority-owned subsidiary to advance its GEAR-modified natural killer (NK) cell therapy into first-in-human studies targeting various cancers and ...
Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed or refractory multiple myeloma commences on track NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, a Replay and MD Anderson ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback